Real-world data on tolerability and clinical response of cemiplimab in patients with advanced cutaneous squamous cell carcinoma: A retrospective, multicentre cohort study from the... by Maartje W. Rohaan, Marleen L. Duizer, Lot A. Devriese, Aafke Meerveld-Eggink, Willem F. Brandts, Johannes V. van Thienen, Sofie Wilgenhof, Carla M.L. van Herpen, John B.A.G. Haanen

Get full text

Tertiary lymphoid structure-related immune infiltrates in NSCLC tumor lesions correlate with low tumor-reactivity of TIL products by Suzanne M. Castenmiller, Nandhini Kanagasabesan, Aurélie Guislain, Benoît P. Nicolet, Marleen M. van Loenen, Kim Monkhorst, Alexander A.F.A. Veenhof, Egbert F. Smit, Koen J. Hartemink, John B.A.G. Haanen, Rosa de Groot, Monika C. Wolkers

Get full text

Art of TIL immunotherapy: SITC’s perspective on demystifying a complex treatment by Robert Brown, Marco Donia, Simon Turcotte, George Coukos, John Mullinax, Brian Gastman, James C Yang, Michael T Lotze, John B A G Haanen, Inge Marie Svane, Stephanie L Goff, Vernon K Sondak, Maartje W Rohaan, Michal Besser, Benjamin Creelan

Get full text

Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up by Annelies Jorritsma-Smit, Michel W J M Wouters, Bianca Heemskerk, Nienke van Rooij, Pia Kvistborg, John B A G Haanen, Joost H van den Berg, Raquel Gomez-Eerland, Samira Michels, Maaike van Zon, Renate de Boer, Noor A M Bakker, Marit M van Buuren, Hergen Spits, Remko Schotte, Henk Mallo, Matthias Karger, Joris A van der Hage, Loes M Pronk, Marnix H Geukes Foppen, Christian U Blank, Jos H Beijnen, Bastiaan Nuijen, Ton N Schumacher

Get full text